Q-linea AB (OSTO:QLINEA) Research & Development: kr0.00 Mil (TTM As of Mar. 2026)


OSTO:QLINEA Q-linea AB OSTO:QLINEA
67 GF Score
Price kr17.60
GF Value kr19.86
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Q-linea AB Research & Development?

Q-linea AB OSTO:QLINEA -2.76% 67 Research & Development is kr0.00 Mil as of Mar. 2026. GuruFocus rates OSTO:QLINEA with a GF Score™ of 67/100 and a GF Value™ of kr19.86 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Q-linea AB's Research & Development for the three months ended in Mar. 2026 was kr0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00 Mil.

Q-linea AB  (OSTO:QLINEA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Q-linea AB Research & Development Related Terms

Q-linea AB Research & Development Historical Data

* Premium members only.

The historical data trend for Q-linea AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q-linea AB Research & Development Chart

Q-linea AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Q-linea AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:QLINEA
67GF Score
Q-linea AB OSTO:QLINEA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q-linea AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr0.00 Mil mean?
Q-linea AB (OSTO:QLINEA) has a Research & Development of kr0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Q-linea AB and its competitors.
Is Q-linea AB's Research & Development too high?
Q-linea AB's current Research & Development is kr0.00 Mil. Overall, Q-linea AB has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's Research & Development compare to ABT and SYK?
Q-linea AB's Research & Development of kr0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Q-linea AB and its competitors. Q-linea AB's current Research & Development is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Based on GuruFocus' analysis, Q-linea AB (OSTO:QLINEA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr19.86, compared to a current price of kr17.60 — trading 11.4% below its estimated fair value. The current Research & Development is kr0.00 Mil. Q-linea AB's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Q-linea AB (OSTO:QLINEA), the current Research & Development is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Q-linea AB (OSTO:QLINEA) Overvalued in 2026?

Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued. The current stock price of kr17.60 is trading 11.4% below its estimated GF Value™ of kr19.86. GuruFocus considers Q-linea AB to be Modestly Undervalued.

Key valuation signals for OSTO:QLINEA:

  • Research & Development: kr0.00 Mil
  • GF Value™: kr19.86 vs. price of kr17.60 (11.4% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the OSTO:QLINEA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Q-linea AB Business Description

Other Exchanges 3F80:Germany
Address Dag Hammarskjolds vag 52 A, Uppsala, SWE, SE-752 37
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
67GF Score

Get the complete analysis for OSTO:QLINEA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr17.60
Price
kr19.86
GF Value